Open AccessPB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL‐AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY
Author(s) -
Raffoux E.,
De Botton S.,
Ades L.,
Carré M.,
Cluzeau T.,
Saillard C.,
Heiblig M.,
Beckerich F.,
Gastaud L.,
Dupuis A.,
Richez U.,
Dumas P.Y.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000850072.95751.61
Subject(s) - medicine , azacitidine , induction chemotherapy , myeloid leukemia , maintenance therapy , placebo , population , hematopoietic stem cell transplantation , transplantation , oncology , chemotherapy , biochemistry , gene expression , environmental health , dna methylation , gene , chemistry , alternative medicine , pathology